Epithelial ovarian carcinoma

Lancet

Volumn 349, Issue 9045, 1997, Pages 113-117

  Kristensen, Gunnar B ^a   Tropé, Claes ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SURVIVAL; FEMALE; HUMAN; INDUSTRIALIZATION; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; OVARY CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0031026893     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(96)06071-0     Document Type: Article

References (12)

1. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994; 44: 7-26.
2. Engeland A, Haldorsen T, Tretli S, et al. Prediction of cancer mortality in the Nordic countries up to the years 2000 and 2010, on the basis of relative survival analysis: a collaborative study of the five Nordic cancer registries. APMIS Suppl 1995; 49: 81-83.
3. Pettersson F. Annual Report on the results of treatment in gynaecological cancer, volume 22, Stockholm: Radiumhemmet, 1995.
4. Whittemore AS. Characteristics relating to ovarian cancer risk: implications for prevention and detection. Gynecol Oncol 1994; 55: S15-19.
5. Franceschi S, Parazzini F, Negri E, et al. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer: III, oral contraceptive use. Int J Cancer 1991; 49: 61-65.
6. NIH consensus conference. Ovarian cancer: screening, treatment, and follow-up. NIH consensus development panel on Ovarian Cancer. JAMA 1995; 273: 491-97.
7. Ford D, Easton DF. The genetics of breast and ovarian cancer. Br J Cancer 1995; 72: 805-12.
8. Godwin AK, Testa JR, Hamilton TC. The biology of ovarian cancer development. Cancer 1993; 71: 530-36.
9. Kaern J, Trope CG, Kristensen GB, Abeler VM, Pettersen EO. DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary. Int J Gynecol Cancer 1993; 3: 349-58.
10. Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 1991; 40: 103-06.
11. Zanetta G, Chiari S, Barigozzi P, Rota S, Losa G, Mangioni C. Limited invasiveness to assess retroperitoneal spread in stage I-II ovarian carcinoma. Int J Gynecol Obstet 1995; 51: 133-10.
12. Hoskins WJ. Primary surgical management of advanced epithelial ovarian cancer. In: Rubin SC, Sutton GP, eds. Ovarian cancer. New York: McGraw-Hill, 1993: 241-53.